Page 924 - Read Online

Mantovani et al. Hepatoma Res 2020;6:78 I http://dx.doi.org/10.20517/2394-5079.2020.75 Page 21 of 22

129. Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann
Transl Med 2017;5:270.
130. Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.
Diabetes Metab Res Rev 2012;28:109-22.
131. Yang WS, Va P, Bray F, et al. The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-
analysis of prospective cohort studies. PLoS One 2011;6:e27326.
132. Petrick JL, Thistle JE, Zeleniuch-Jacquotte A, et al. Body mass index, diabetes and intrahepatic cholangiocarcinoma risk: the liver cancer
pooling project and meta-analysis. Am J Gastroenterol 2018;113:1494-505.
133. Huang YJ, Wu AT, Chiou HY, et al. Interactive role of diabetes mellitus and female sex in the risk of cholangiocarcinoma: a population-
based nested case-control study. Oncotarget 2017;8:6642-51.
134. Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver
disease. Nat Rev Gastroenterol Hepatol 2018;15:425-39.
135. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-
analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
136. Paik JM, Henry L, De Avila L, Younossi E, Racila A, Younossi ZM. Mortality related to nonalcoholic fatty liver disease is increasing in
the United States. Hepatol Commun 2019;3:1459-71.
137. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a
meta-analysis. J Hepatol 2016;65:589-600.
138. Meyersohn NM, Mayrhofer T, Corey KE, et al. Association of hepatic steatosis with major adverse cardiovascular events, independent of
coronary artery disease. Clin Gastroenterol Hepatol 2020:S1542-3565(20)30992-7.
139. Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular
hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest 2012;35:215-8.
140. Rossi A, Targher G, Zoppini G, et al. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in
patients with type 2 diabetes. Diabetes Care 2012;35:1781-6.
141. Mantovani A, Dauriz M, Sandri D, et al. Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult
individuals: An updated meta-analysis. Liver Int 2019;39:758-69.
142. Mantovani A. Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis. J Clin
Transl Hepatol 2017;5:134-41.
143. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the
American Association for the Study of Liver Diseases. Hepatology 2018;67:328-57.
144. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association
for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver
disease. J Hepatol 2016;64:1388-402.
145. Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol 2020;72:785-801.
146. Jia G, Di F, Wang Q, et al. Non-Alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with
type 2 diabetes mellitus. PLoS One 2015;10:e0142808.
147. Nampoothiri RV, Duseja A, Rathi M, et al. Renal dysfunction in patients with nonalcoholic fatty liver disease is related to the presence of
diabetes mellitus and severity of liver disease. J Clin Exp Hepatol 2019;9:22-8.
148. Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of kidney dysfunction in NAFLD. Curr Pharm Des 2020;26:1045-61.
149. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc
Nephrol 2008;19:1564-70.
150. Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic
review and meta-analysis. Metabolism 2018;79:64-76.
151. Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM. Chronic kidney disease is independently associated with increased
mortality in patients with nonalcoholic fatty liver disease. Liver Int 2019;39:342-52.
152. Önnerhag K, Dreja K, Nilsson PM, Lindgren S. Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is
explained by metabolic comorbidities. Clin Res Hepatol Gastroenterol 2019;43:542-50.
153. Mantovani A, Taliento A, Zusi C, et al. PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD:
Clinical and experimental findings. Liver Int 2020;40:1130-41.
154. Lv WS, Sun RX, Gao YY, et al. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J
Gastroenterol 2013;19:3134-42.
155. Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic
patients with non-alcoholic fatty liver disease. J Diabetes Investig 2014;5:170-5.
156. Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link? Mol Cell Endocrinol
2015;418 Pt 1:55-65.
157. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.
Hepatology 2009;49:1877-87.
158. Beserra BT, Fernandes R, do Rosario VA, Mocellin MC, Kuntz MG, Trindade EB. A systematic review and meta-analysis of the
prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity.
Clin Nutr 2015;34:845-58.